Pharma Stocks
Laurus Labs stock jumps 2%, hits new high on 125% surge in Q1 profit
Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.
 "Laurus Labs stock jumps 2%, hits new high on 125% surge in Q1 profit")
Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?
Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.
 "Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?")
Trump's 200% tariffs on imported generic medicines to test India's edge
Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period
 "Trump's 200% tariffs on imported generic medicines to test India's edge")
Divi's Labs rallies 3%, market cap nears ₹2 trillion; what's driving stock?
As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.
 "Divi's Labs rallies 3%, market cap nears ₹2 trillion; what's driving stock?")
Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?
The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product
 "Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?")
Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial
Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.
 "Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial")
Aurobindo Pharma nears all-time high, up 30% in 4 months; more upside left?
Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.
 "Aurobindo Pharma nears all-time high, up 30% in 4 months; more upside left?")
Dr Reddys gains over 4%; hits 52-week high on near 3X jump in volume
Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.
 "Dr Reddys gains over 4%; hits 52-week high on near 3X jump in volume")
Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%
Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.
 "Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%")
Aurobindo Pharma stock jumps 2% after US FTC approves Lannett acquisition
Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.
 "Aurobindo Pharma stock jumps 2% after US FTC approves Lannett acquisition")
New launches, India business growth key triggers for Zydus Lifesciences
Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27
 "New launches, India business growth key triggers for Zydus Lifesciences")
Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue
Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period
 "Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue")
Pharma, healthcare funds are in recovery mode. Should you enter them now?
Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent
 "Pharma, healthcare funds are in recovery mode. Should you enter them now?")
Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here
Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period
Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%
Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25
Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?
In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent
 "Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?")
Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why
Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
 "Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why")
Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential
Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook
 "Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential")
Pharma cos brace for soft Q4; US drag persists; domestic growth cushions
Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements
 "Pharma cos brace for soft Q4; US drag persists; domestic growth cushions")
Sun Pharma stock falls 5% in strong market: What's worrying investors?
Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook